An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression
Phase of Trial: Phase III
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Esketamine (Primary) ; Duloxetine; Escitalopram; Sertraline; Venlafaxine
- Indications Major depressive disorder
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SUSTAIN-2
- Sponsors Janssen Research & Development
- 22 Nov 2017 Status changed from recruiting to completed.
- 09 Nov 2017 This trial has been completed in Germany (end date: 30 Oct 2017).
- 08 Nov 2017 This trial has been completed in Belgium (2017-09-28), according to European Clinical Trials Database.